Vonoprazan/amoxicillin
< Vonoprazan
| Combination of | |
|---|---|
| Vonoprazan | Potassium-competitive acid blocker |
| Amoxicillin | Beta-lactam antibiotic |
| Clinical data | |
| Trade names | Voquezna Dual Pak |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
Vonoprazan/amoxicillin, sold under the brand name Voquezna Dual Pak among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection. It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker and amoxicillin, a beta-lactam antibiotic. It is taken by mouth.
The co-packaged medication was approved for medical use in the United States in May 2022.